EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhancing Radiation Therapy Response in Prostate Cancer Through Metabolic Modulation by Mito-Lonidamine: A 1H and 31P Magnetic Resonance Spectroscopy Study

Stepan Orlovskiy iD, Pradeep Kumar Gupta iD, Fernando Arias-Mendoza, Dinesh Kumar Singh, Skyler Nova, David S Nelson iD, Vivek Narayan iD, Cameron J Koch, Micael Hardy iD, Ming You iD, Balaraman Kalyanaraman iD, Kavindra Nath iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26020509 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Stepan Orlovskiy und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiation-Sensitizing Agents, Organophosphorus Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NCI NIH HHS, NIH and University of Pennsylvania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiation therapy (RT) is the cornerstone treatment for prostate cancer; however, it frequently induces gastrointestinal and genitourinary toxicities that substantially diminish the patients’ quality of life. While many individuals experience transient side effects, a subset endures persistent, long-term complications. A promising strategy to mitigate these toxicities involves enhancing tumor radiosensitivity, potentially allowing for lower radiation doses. In this context, mito-lonidamine (Mito-LND), an antineoplastic agent targeting the mitochondrial electron transport chain’s complexes I and II, emerges as a potential radiosensitizer. This study investigated Mito-LND’s capacity to augment RT efficacy and reduce adverse effects through comprehensive in vitro and in vivo assessments using hormone-sensitive and hormone-refractory prostate cancer models. Employing a Seahorse analysis and 1H/31P magnetic resonance spectroscopy (MRS), we observed that Mito-LND selectively suppressed lactate production, decreased intracellular pH, and reduced bioenergetics and oxygen consumption levels within tumor cells. These findings suggest that Mito-LND remodels the tumor microenvironment by inducing acidification, metabolic de-energization, and enhanced oxygenation, thereby sensitizing tumors to RT. Our results underscore the potential of Mito-LND as a therapeutic adjunct in RT to improve patient outcomes and reduce radiation-associated toxicities in early-stage prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsRadiation-Sensitizing AgentsOrganophosphorus CompoundsMaleHumansAnimalsCell Line, TumorMiceMagnetic Resonance SpectroscopyEnergy MetabolismTumor MicroenvironmentMitochondriaIndazoles

Stichwörter der Autor:innen

lonidaminemagnetic resonance imagingmagnetic resonance spectroscopymetabolic modulationmito-lonidamineprostate cancerradiation therapy

Substanzen

Radiation-Sensitizing AgentsOrganophosphorus CompoundslonidamineIndazoles

Autor:innen und Institutionen

  • Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Advanced Imaging Research Inc., Cleveland, OH 44114, USA.
  • Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Département de Chimie, Aix-Marseille University, CNRS, ICR, UMR 7273, 13013 Marseille, France.
  • Center for Cancer Prevention, Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston, TX 77030, USA.

ORCID-Profile: Stepan Orlovskiy, Pradeep Kumar Gupta, David S Nelson, Vivek Narayan, Micael Hardy, Ming You, Balaraman Kalyanaraman, Kavindra Nath

Förderung

  • NCATS NIH HHS
  • NCI NIH HHS
  • NIH and University of Pennsylvania
  • Institute for Translational Medicine and Therapeutics
  • NIH

Zitieren

APA

Orlovskiy, S., Gupta, P. K., Arias-Mendoza, F., Singh, D. K., Nova, S., Nelson, D. S., Narayan, V., Koch, C. J., Hardy, M., You, M., Kalyanaraman, B., & Nath, K. (2025). Enhancing Radiation Therapy Response in Prostate Cancer Through Metabolic Modulation by Mito-Lonidamine: A 1H and 31P Magnetic Resonance Spectroscopy Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26020509

Vancouver

Orlovskiy S, Gupta PK, Arias-Mendoza F, Singh DK, Nova S, Nelson DS, et al. Enhancing Radiation Therapy Response in Prostate Cancer Through Metabolic Modulation by Mito-Lonidamine: A 1H and 31P Magnetic Resonance Spectroscopy Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26020509

BibTeX
@article{Orlovskiy2025,
  author = {Orlovskiy, Stepan and Gupta, Pradeep Kumar and Arias-Mendoza, Fernando and Singh, Dinesh Kumar and Nova, Skyler and Nelson, David S and Narayan, Vivek and Koch, Cameron J and Hardy, Micael and You, Ming and Kalyanaraman, Balaraman and Nath, Kavindra},
  title = {Enhancing Radiation Therapy Response in Prostate Cancer Through Metabolic Modulation by Mito-Lonidamine: A 1H and 31P Magnetic Resonance Spectroscopy Study},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26020509}
}
Kostenlos starten →